HHS发布执法裁量政策,临时允许配制部分未获批肽类产品
STAT+: HHS moves to allow compounding of some unapproved peptides
美国卫生与公众服务部(HHS)发布政策,临时允许配制药房生产部分肽类产品,并称将以执法裁量方式不对州许可药房、联邦机构和持照医生配制六种肽类产品采取行动。这六种肽类此前获FDA顾问委员会支持,而FDA仍在评估是否允许配制药房生产这些物质;7月一个FDA顾问小组投票建议放行其中六种。原文称该政策扩大了MAHA运动中不少人使用的实验性健康疗法的可及性。
WASHINGTON — The Department of Health and Human Services released a policy that will temporarily allow compounding pharmacies to manufacture some peptide products, increasing access to the experimental wellness therapies embraced by many in the MAHA movement.
The policy states that HHS will use “enforcement discretion” to not take action against state-licensed pharmacies, federal facilities, or licensed physicians compounding the six peptides previously backed by a Food and Drug Administration advisory committee.
The proposal comes as the FDA continues to weigh whether to allow compounding pharmacies to manufacture peptides. In July, an FDA advisory panel voted to recommend that these pharmacies be cleared to manufacture six of these substances.
STAT+ Exclusive Story
Already have an account? Log in

This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.
Already have an account? Log in
To read the rest of this story subscribe to STAT+.
来源:STAT Pharma 医药频道 · statnews.com